Clinical Trial Update: Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and immunogenicity of a prime-boost HIV vaccine regimen (426c.Mod.Core-C4b prime followed by HxB2.WT.Core-C4b boost…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• 3M-052 AF (TLR7/8 agonist adjuvant)
• 426c.Mod.Core-C4b
• Alum (aluminum-based adjuvant)
• HxB2.WT.Core-C4b

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV | Phase 1 | Status: RECRUITING